<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46864">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01856127</url>
  </required_header>
  <id_info>
    <org_study_id>VII-IT-09</org_study_id>
    <secondary_id>VII-IT-09</secondary_id>
    <nct_id>NCT01856127</nct_id>
  </id_info>
  <brief_title>Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?</brief_title>
  <official_title>A Randomized, Double-Blind, Active Controlled Clinical Trial of Switching to Vilazodone for Antidepressant-Associated Sexual Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a three-center, randomized, double-blind, fixed dose study designed to assess the
      efficacy, safety, and tolerability of a switch to vilazodone for sexual dysfunction
      associated with use of a selective serotonin reuptake inhibitor (SSRI) and
      serotonin-norepinephrine reuptake inhibitor (SNRI)compared to switching to sertraline in
      patients with Major Depressive Disorder (MDD).

      Vilazodone is a newly introduced, FDA approved antidepressant that is a combined serotonin
      specific reuptake inhibitor and serotonin 1A receptor partial agonist. In contrast to the
      SSRIs and SNRIs, appears to have low adverse effects on sexual functioning when compared to
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design will be a randomized, double blind study with patients being randomized to
      switching to either vilazodone or sertraline. This will consist of a 1-week Screening phase,
      a 2-week Cross Taper phase, an 8-week Treatment phase, and an optional 2-week Down taper
      phase. The total duration of each patient's participation will be 13 weeks.

      Seventy-two patients will be randomized at the Baseline visit to either vilazodone or
      sertraline, 24 at each of the 3 sites. Patients will be recruited over 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in Sexual Functioning Questionnaire (CSFQ (c))</measure>
    <time_frame>Baseline-11 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Sexual Dysfunction</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Vilazodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vilazodone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sertraline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilazodone</intervention_name>
    <description>Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning</description>
    <arm_group_label>Vilazodone</arm_group_label>
    <other_name>Viibryd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.</description>
    <arm_group_label>Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able to understand the nature of the study, agree to comply with the
             prescribed dosage regimens, report for regularly scheduled office visits, and
             communicate to study personnel about adverse events and concomitant medication use;

          2. Patients with major depressive disorder who are being treated with a selective
             serotonin reuptake inhibitor (citalopram, escitalopram, fluvoxamine, or paroxetine)
             or serotonin-norepinephrine reuptake inhibitor (desvenlafaxine, duloxetine,
             venlafaxine) for a minimum of 8 weeks.

          3. The current episode of MDD is in remission (MADRS score &lt; 10 and CGI score of 1 or 2)

          4. The duration of the current MDD episode is less than 2 years

          5. Presence of antidepressant-associated sexual dysfunction (i.e., absence of sexual
             dysfunction prior to becoming depressed and presence of significant dysfunction while
             on the SSRI or SNRI despite being in remission from the depression).

          6. Patient is at least 18 years old and not more than 65 years old

          7. Patients must have the opportunity for sexual activity during the study period (in
             the form of availability of a suitable partner for sexual activity and/or openness to
             masturbation)

          8. Patients must be willing to attempt some sexual activity (including masturbation) at
             least once every two weeks during the study

        Exclusion Criteria:

          1. Patients who have previously failed to respond to or to tolerate either vilazodone or
             sertraline.

          2. Patients with a history of severe discontinuation symptoms on tapering off the
             current antidepressant

          3. Patients with other known causes of sexual dysfunction

          4. Use of prohibited medications during the study period
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rajnish Mago, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Thase, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anita Clayton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajnish Mago, MD</last_name>
    <phone>215-955-9474</phone>
    <email>rajnish.mago@jefferson.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly Huhn, BS</last_name>
    <phone>215-503-1662</phone>
    <email>kelly.huhn@jefferson.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Huhn, BS</last_name>
      <phone>215-503-1662</phone>
      <email>kelly.huhn@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tania Ruggiero</last_name>
      <phone>215-955-9474</phone>
      <email>tania.ruggiero@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rajnish Mago, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lalita Luthra</last_name>
      <phone>215-746-6419</phone>
      <email>luthra@mail.med.upenn.edu &lt;luthra@mail.med.upenn.edu&gt;;</email>
    </contact>
    <investigator>
      <last_name>Michael Thase, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dea Papajorgji</last_name>
      <phone>434-243-4646</phone>
      <email>DP3FC@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Anita Clayton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sexual Dysfunction</keyword>
  <keyword>Antidepressant</keyword>
  <keyword>Major Depressant</keyword>
  <keyword>SSRI</keyword>
  <keyword>SNRI</keyword>
  <keyword>Vilazodone</keyword>
  <keyword>Sertraline</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Sexual Dysfunctions, Psychological</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
